ATRA241220P1000
- 0.00
- 0.000.00%
Atara Biotherapeutics Newsroom
Insider Sale: EVP of $ATRA (ATRA) Sells 1,000 Shares
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Raises Target Price to $21
Atara Biotherapeutics Price Target Raised to $21 From $13 at Canaccord
Atara Biotherapeutics Advances With Strategic Partnerships
Atara Biotherapeutics | 8-K: Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Atara Biotherapeutics: Cash Runway Into 2027 Enables Key Pipeline Readouts >ATRA
Atara Biotherapeutics: First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected 1Q of 2025 >ATRA
Atara Biotherapeutics: Tab-cel U.S. BLA On-Track With PDUFA Target Action Date of Jan 15, 2025 >ATRA
Atara Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Atara Biotherapeutics Reports Q3 EPS ($2.93), Consensus ($1.93)
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M
Express News | Atara Biotherapeutics Q3 Revenue USD 40.19 Million Vs. IBES Estimate USD 35.2 Million
Express News | Atara Biotherapeutics Q3 Net Income USD -21.909 Million
Here Are the Major Earnings After the Close Today
Insights Into Atara Biotherapeutics's Upcoming Earnings
Earnings Preview: ATRA to Report Financial Results Post-market on November 12
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Express News | Atara Biotherapeutics- Appointed Eric Hyllengren to Serve as Chief Operating Officer, in Addition to Role as CFO
Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc